Latest Period
Q1 2026
Security Snapshot
Forte Biosciences, Inc. - Common Stock (FBRX) Institutional Ownership
CUSIP: 34962G208
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
68
Shares (Excl. Options)
13,521,022
Price
$25.90
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- FBRX on Nasdaq
- Shares outstanding
- 6,120,451
- Price per share
- $24.29
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 13,521,022
- Total reported value
- $350,237,410
- % of total 13F portfolios
- 0%
- Share change
- +1,985,279
- Value change
- +$50,671,169
- Number of holders
- 68
- Price from insider filings
- $24.29
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- FBRX - Forte Biosciences, Inc. - Common Stock is tracked under CUSIP 34962G208.
- 68 institutions reported positions in Q1 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 59 to 68 between Q4 2025 and Q1 2026.
- Reported value moved from $314,510,108 to $350,237,410.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 68 institutions filings for Q1 2026.
Security key
34962G208
Latest holder period
Q1 2026
13F holders
68
13D/G owners
12
CIK / CUSIP context first
Open Q1 2026 holders
FBRX full holder history
Forte Biosciences, Inc. SEC filings
Forte Biosciences, Inc. company facts
Forte Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 34962G208:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
12
Security
FBRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | 13% | +10% | $18,692,393 | +$1,791,458 | 1,635,380 | +11% | Federated Hermes, Inc. | 30 Sep 2025 |
| JANUS HENDERSON GROUP PLC | 10% | -13% | $47,025,334 | -$1,308,777 | 1,387,178 | -2.7% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 10% | 0% | $13,378,307 | +$6,618,184 | 1,268,086 | +98% | TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 30 Jun 2025 |
| Affinity Asset Advisors, LLC | 6.7% | -2.9% | $22,251,791 | -$731,169 | 834,964 | -3.2% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| Point72 Asset Management, L.P. | 6.3% | $21,132,810 | 792,976 | Point72 Asset Management, L.P. | 12 Jan 2026 | |||
| ALGER ASSOCIATES INC | 10% | -22% | $21,163,295 | -$34,238,356 | 624,286 | -62% | Alger Associates, Inc. | 31 Mar 2026 |
| Ikarian Capital, LLC | 5% | -45% | $6,516,387 | +$89,063 | 617,667 | +1.4% | Ikarian Capital, LLC | 30 Jun 2025 |
| ORBIMED ADVISORS LLC | 8% | $3,763,800 | 510,000 | ORBIMED ADVISORS LLC | 31 Dec 2024 | |||
| Oliveira Steven Michael | 2.4% | -62% | $6,797,265 | -$2,993,786 | 300,100 | -31% | Oliveira Steven Michael | 08 Jan 2026 |
| PERCEPTIVE ADVISORS LLC | 2.5% | $1,209,840 | 163,935 | Perceptive Advisors LLC | 31 Dec 2024 | |||
| BIOTECHNOLOGY VALUE FUND L P | 0.5% | -95% | $980,250 | -$8,674,080 | 65,350 | -90% | BVF PARTNERS L P/IL | 30 Sep 2025 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.8% | -87% | $567,495 | -$369,187 | 53,791 | -39% | Boothbay Fund Management, LLC | 30 Jun 2025 |
As of 31 Mar 2026, 68 institutional investors reported holding 13,521,022 shares of Forte Biosciences, Inc. - Common Stock (FBRX). This represents 221% of the company’s total 6,120,451 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
205%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | 29% | 1,765,516 | 0% | 0.07% | $45,726,864 |
| FRED ALGER MANAGEMENT, LLC | 21% | 1,273,965 | -13% | 0.14% | $32,995,694 |
| ORBIMED ADVISORS LLC | 20% | 1,196,955 | 0% | 0.7% | $31,001,135 |
| JANUS HENDERSON GROUP PLC | 19% | 1,188,060 | -17% | 0.01% | $30,812,336 |
| Affinity Asset Advisors, LLC | 17% | 1,011,890 | +2.3% | 1.5% | $26,207,951 |
| MPM BIOIMPACT LLC | 16% | 1,000,682 | 2% | $25,917,664 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 16% | 950,000 | +185% | 0.04% | $24,605,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 8.7% | 531,692 | 0% | 0% | $13,770,823 |
| MORGAN STANLEY | 8.2% | 500,298 | +609% | 0% | $12,957,718 |
| Cable Car Capital, LP | 6.5% | 400,000 | 0% | 3.6% | $10,360,000 |
| FMR LLC | 5.6% | 340,695 | +9.6% | 0% | $8,824,001 |
| MILLENNIUM MANAGEMENT LLC | 5.5% | 337,983 | +37% | 0.01% | $8,753,760 |
| Woodline Partners LP | 5.4% | 331,987 | 0% | 0.03% | $8,598,463 |
| CITADEL ADVISORS LLC | 3.8% | 233,369 | 0% | $6,044,257 | |
| AWM Investment Company, Inc. | 3.3% | 200,000 | -16% | 0.57% | $5,180,000 |
| SPHERA FUNDS MANAGEMENT LTD. | 3% | 184,984 | -0.48% | 0.82% | $4,791,086 |
| MARSHALL WACE, LLP | 2.5% | 150,307 | +314% | 0% | $3,892,953 |
| Integral Health Asset Management, LLC | 2.5% | 150,000 | 0.21% | $3,885,000 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.2% | 133,494 | +152% | 0% | $3,457,495 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 125,442 | +0.67% | 0% | $3,250,628 |
| Ikarian Capital, LLC | 1.9% | 118,972 | -60% | 0.44% | $3,081,376 |
| LORD, ABBETT & CO. LLC | 1.9% | 114,635 | 0.01% | $2,969,000 | |
| AMERIPRISE FINANCIAL INC | 1.8% | 111,788 | -27% | 0% | $2,895,310 |
| Russell Investments Group, Ltd. | 1.5% | 91,772 | 0% | $2,376,918 | |
| Qube Research & Technologies Ltd | 1.4% | 85,969 | +167% | 0% | $2,226,597 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Latest
Q1 2026
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 13,521,022 | $350,237,410 | +$50,671,169 | $25.90 | 68 |
| 2025 Q4 | 11,522,905 | $314,510,108 | +$55,513,195 | $27.27 | 59 |
| 2025 Q3 | 10,343,866 | $155,080,846 | +$6,727,909 | $15.00 | 42 |
| 2025 Q2 | 9,809,779 | $127,063,335 | +$62,289,077 | $12.93 | 33 |
| 2025 Q1 | 5,034,489 | $39,316,245 | +$4,704,465 | $7.76 | 29 |
| 2024 Q4 | 4,275,821 | $97,104,372 | +$81,936,549 | $22.71 | 26 |
| 2024 Q3 | 736,630 | $4,120,236 | +$4,082,162 | $5.59 | 23 |